Mediwound Ltd. revenue

Mediwound Ltd.'s revenue was $17.0m in fiscal 2025, down 16.1% on the year before. Since fiscal 2015 ($601,000) it has grown at a compound 39.7% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Mediwound Ltd.: revenue history, annual
Fiscal year	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	1	2	2	3	32	22	24	26	19	20	17
Growth on the year before	—	+159.2%	+60.2%	+36.3%	+834.7%	−31.5%	+9.2%	+11.5%	−29.5%	+8.2%	−16.1%
Gross profit	−2	−1	1	1	20	8	9	13	4	3	3
Gross margin	—	−38.5%	36.8%	38.6%	62.7%	34.7%	36.9%	49.7%	19.1%	13.0%	19.2%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Mediwound Ltd.	$17.0m	-16.1%	—
Proqr Therapeutics N.V.	$18.0m	-12.1%	—
Cytomx Therapeutics, Inc.	$18.3m	-87.0%	-38.7%
Celularity Inc	$18.7m	-58.1%	7.2%
Scynexis Inc	$19.2m	489.8%	-47.9%
Keros Therapeutics, Inc.	$14.9m	-93.6%	—

Compare with peers

Head to head: MDWD vs PRQR CTMX vs MDWD CELU vs MDWD

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Mediwound Ltd.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Mediwound Ltd.